Inhibitors

Hecogenin
Catalog No: CFN98586

Hecogenin, a steroid saponin isolated from Agave sisalana, is a potent and highly selective inhibitor of UGT1A4 with an IC50 value of 1.5 μM. Hecogenin has anti-cancer, antiproliferative,antioxidant and anti-inflammatory effects, it can protect gastro by K⁺(ATP) channels opening and the COX-2/PG pathway. Hecogenin has inhibition of human rheumatoid arthritis synovial cell survival, the effect is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2.

Rasagiline mesylate
Catalog No: CFN90004

Rasagiline mesylate is a potent, selective, non-reversible MAO-B inhibitor, with neuroprotective activities, with anti-Parkinson activity. Rasagiline mesylate exhibits neuroprotective and anti-apoptotic activity against several neurotoxins in cell culture.

5-Aza-2'-deoxycytidine
Catalog No: CFN90007

1. Decitabine (5-Aza-2'-deoxycytidine) is a DNA methyltransferase inhibitor and an archetypal epigenetic drug for the therapy of myeloid leukemias.
2. Aza-2'-deoxycitidine exerts its anti-tumor effects in hepatocellular carcinoma(HCC) cells by inhibiting the telomerase activity.

Palonosetron hydrochloride
Catalog No: CFN90009

Palonosetron hydrochloride is the only serotonin receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderate emetogenic chemotherapy (MEC).

Canertinib
Catalog No: CFN90010

Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Canertinib displays anti-proliferative and pro-apoptotic effects in human myeloid leukemia cells devoid of ErbB-receptors, downregulates important signaling pathways and activates caspase-mediated intrinsic apoptosis pathway in human T-cell leukemia cells.